Inovatyvios dermatologijos centras, UAB - financials and debts

Company age: 16 y. 3 mo.

Update

Inovatyvios dermatologijos centras - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 513,182 681,553 820,820 1,511,639 1,949,130 2,185,611 2,415,781 2,815,824
Profit before tax 39,384 42,334 177,093 415,189 342,927 -302,223 -4,454 24,757
Net profit 37,360 42,334 160,374 396,163 342,927 -302,223 -4,454 24,757
Equity 14,094 56,429 216,803 612,966 955,893 653,668 649,214 673,971
Liabilities - - - - 2,563,254 4,456,384 4,230,405 4,004,284
Non-current assets 199,704 233,793 164,478 1,676,247 3,364,335 4,937,435 4,694,832 4,505,347
Current assets 14,331 13,548 178,189 95,097 154,812 172,617 184,787 172,908
Total assets 214,035 247,341 342,667 1,771,344 3,519,147 5,110,052 4,879,619 4,678,255
Taxes paid
STI taxes - - - - - - 269,049 358,462
Social insurance contributions - - - - - 212,270 240,540 271,380
Financial indicators
Revenue change y/y +66.1% +32.8% +20.4% +84.2% +28.9% +12.1% +10.5% +16.6%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 17.5% 17.1% 46.8% 22.4% 9.7% -5.9% -0.1% 0.5%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 265.1% 75.0% 74.0% 64.6% 35.9% -46.2% -0.7% 3.7%
Profit margin Net profit margin. Shows the overall profitability of the company. 7.3% 6.2% 19.5% 26.2% 17.6% -13.8% -0.2% 0.9%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 7.7% 6.2% 21.6% 27.5% 17.6% -13.8% -0.2% 0.9%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. - - - - 2.7 6.8 6.5 5.9
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 42,470 47,275 43,583 70,858 79,556 59,472 65,145 68,818

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Inovatyvios dermatologijos centras - Social security debts

The amount of overdue SODRA debt for the company Inovatyvios dermatologijos centras as of the last working day is: 60 €

From To Debt, €
2026-09-11 2026-09-15 59.92
2026-08-23 2026-08-23 4953.13
2026-08-19 2026-08-19 21953.13
2026-07-19 2026-07-20 8056.64
2026-07-16 2026-07-17 23610.64
2026-06-18 2026-06-21 7051.42
2026-06-17 2026-06-17 13051.42
2026-06-16 2026-06-16 20051.42
2026-06-11 2026-06-14 32.21
2026-05-22 2026-06-08 32.21
2026-05-18 2026-05-19 16523.93
2026-05-17 2026-05-17 18523.93
2026-03-27 2026-03-27 8878.85
2026-03-17 2026-03-18 8878.85
2026-02-24 2026-02-26 4584.99
2026-02-22 2026-02-23 7584.99
2026-02-20 2026-02-21 17584.99
2026-02-19 2026-02-19 21982.99
2026-02-18 2026-02-18 23544.99
2026-01-21 2026-01-21 3376.92
2026-01-20 2026-01-20 7666.92
2026-01-16 2026-01-19 17666.92
2025-12-18 2025-12-21 10503.30
2025-12-17 2025-12-17 14503.30
2025-12-16 2025-12-16 21564.30
2025-11-20 2025-11-20 8893.06
2025-11-19 2025-11-19 16005.06
2025-11-18 2025-11-18 21545.06
2025-10-20 2025-10-20 9127.42
2025-10-19 2025-10-19 10127.42
2025-10-17 2025-10-18 19527.42
2025-10-16 2025-10-16 20471.42
2025-09-19 2025-09-21 9546.36
2025-09-18 2025-09-18 13646.36
2025-09-17 2025-09-17 17546.36
2025-09-16 2025-09-16 20646.36
2025-08-28 2025-08-29 21089.88
2025-08-21 2025-08-21 7650.88
2025-08-19 2025-08-20 21089.88
2025-07-17 2025-07-20 12483.98
2025-07-16 2025-07-16 18040.34
2025-06-17 2025-06-17 14787.74
2025-05-16 2025-05-18 12610.42
2025-04-17 2025-04-21 7751.92
2025-04-16 2025-04-16 12751.92
2025-03-18 2025-03-18 17947.99
2025-02-19 2025-02-19 1994.06
2025-02-18 2025-02-18 14470.06
2025-01-22 2025-01-22 6750.64
2025-01-21 2025-01-21 10050.64
2025-01-19 2025-01-20 12550.64
2025-01-18 2025-01-18 13304.64
2025-01-16 2025-01-17 15704.64
2024-12-22 2024-12-22 1390.47
2024-12-18 2024-12-20 12390.47
2024-12-17 2024-12-17 16140.47
2024-11-28 2024-11-28 1916.95
2024-11-26 2024-11-27 6566.95
2024-11-25 2024-11-25 7316.95
2024-11-22 2024-11-24 12666.95
2024-11-21 2024-11-21 16466.95
2024-11-20 2024-11-20 16925.95
2024-11-19 2024-11-19 17134.95
2024-11-18 2024-11-18 17616.95
2024-10-18 2024-10-20 2511.67
2024-10-17 2024-10-17 8511.67
2024-10-16 2024-10-16 14111.67
2024-09-20 2024-09-22 274.84
2024-09-19 2024-09-19 5674.84
2024-09-18 2024-09-18 13174.84
2024-09-17 2024-09-17 20906.84
2024-08-23 2024-08-25 3439.69
2024-08-22 2024-08-22 8922.69
2024-08-21 2024-08-21 12439.69
2024-08-20 2024-08-20 17569.69
2024-08-19 2024-08-19 18919.69
2024-07-16 2024-07-30 18954.59
2023-04-18 2023-04-23 63.74
2022-09-16 2022-10-13 2.71
2022-08-23 2022-09-14 2.71
2022-05-17 2022-05-26 136.54
2022-04-19 2022-05-10 109.97
2022-03-16 2022-04-12 88.35
2022-02-17 2022-02-27 56.60
2021-11-16 2021-11-23 10.09

Inovatyvios dermatologijos centras - VMI tax arrears

From To Overdue, €
2026-08-18 2026-08-19 3949.54
2026-02-21 2026-02-21 15315.49
2026-02-18 2026-02-20 15955.51
2025-11-18 2025-11-18 4492.38
2025-10-16 2025-10-18 8943.65
2025-09-17 2025-09-17 15102.54
2025-08-19 2025-08-19 7950.85
2025-07-27 2025-07-27 827.45
2025-07-26 2025-07-26 4756.02
2025-07-24 2025-07-25 4770.23
2025-07-23 2025-07-23 7192.79
2025-07-22 2025-07-22 12980.19
2025-07-16 2025-07-20 5544.68
2024-12-17 2024-12-17 7745.24
2024-11-28 2024-11-28 2973.39
2024-11-27 2024-11-27 1792.49
2024-11-22 2024-11-26 1790.24
2024-11-20 2024-11-21 8341.04
2024-11-18 2024-11-19 12603.04
2024-11-17 2024-11-17 12413.04

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Inovatyvios dermatologijos centras, UAB (company code 302519484) is a Private Limited Liability Company engaged in medical specialists activities. In 2025, the company generated revenue of €2.82M, up 16.6% year on year and 28.8% over two years. Profitability improved materially: after a net loss of €302.2K in 2023 and a near-breakeven loss of €4.5K in 2024, the company reported a net profit of €24.8K in 2025, with a profit margin of 0.9%. The balance sheet remained stable, with total assets of €4.68M, equity of €674.0K and liabilities of €4.00M. Long-term assets accounted for most of the asset base at €4.51M, while short-term assets were €172.9K. Key ratios for 2025 show moderate efficiency and limited leverage support, with ROE at 3.7%, ROA at 0.5%, debt-to-equity at 5.94 and asset turnover at 0.60x. Revenue per employee was €70.4K and profit per employee €619, indicating modest operating profitability in the latest year.